By Stephen Levin
Given all of the success that Guidant Corp. achieved with bare metal coronary stents—it was the overall stent market...
Guidant Pioneers Stents' Move North to Carotids
Stenting moves from coronaries to carotids to do for stroke what these devices did for heart attacks. This new endovascular approach has surgeons switching, not fighting.
More from Innovation
More from In Vivo
• By
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
• By
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.